Five Key Numbers Explain Why Micron Is Different This Time



If you had to summarize Micron's trillion-dollar milestone with just five numbers, these are the ones I would choose.

The first is 48. Micron took only 48 trading days to go from a $500 billion market cap to over $1 trillion, ten times faster than NVIDIA. The second is 800%. The stock has surged about 8-fold over the past year, making it one of the fastest-growing companies in the trillion-dollar club. The third is 196%. Revenue soared 196% year-over-year, reaching $23.9 billion, far exceeding market expectations of $19.2 billion. The fourth is 15 times. The forward P/E ratio is 15 times, much cheaper than peers often trading at 30 or even 40 times. The fifth is $1.8 trillion. This is the 12-month target market cap set by UBS.

Even U.S. President Trump publicly said at a rally last weekend, "Wow, Micron is amazing, they are investing hundreds of billions of dollars." When the president is out promoting a stock, it’s hard not to see it rise.

However, rationally speaking, the cyclical nature of the memory chip industry has not completely disappeared. Long-term supply agreements can lock in profits to some extent, but if the global economy suddenly slows down and companies cut back on AI capital expenditures, demand for memory chips will still be affected. When that happens, the stock price could fall more sharply than typical tech stocks. So I wouldn’t consider Micron a long-term legendary story to hold for ten years—key is to watch for changes in supply and demand. At least until the first half of next year, there are no signs of slowing down in the AI infrastructure boom.

#美光市值突破1万亿美元
$MU
MU29.38%
View Original
post-image
post-image
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments